Raymond James Financial
CRSP icon

Raymond James Financial’s CRISPR Therapeutics CRSP Stock Holding History

Raymond James Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Buy
231,988
+11,714
+5% +$617K ﹤0.01% 1952
2026
Q1 		$10.5M Buy
220,274
+53,126
+32% +$2.8M ﹤0.01% 1979
2025
Q4 		$8.77M Buy
167,148
+57,318
+52% +$3.43M ﹤0.01% 2084
2025
Q3 		$7.12M Buy
109,830
+12,257
+13% +$704K ﹤0.01% 2196
2025
Q2 		$4.75M Buy
97,573
+10,907
+13% +$422K ﹤0.01% 2410
2025
Q1 		$2.95M Buy
86,666
+4,571
+6% +$194K ﹤0.01% 2702
2024
Q4 		$3.23M Buy
+82,095
New +$3.88M ﹤0.01% 2615

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raymond James Financial's CRSP Position: Q2 2026 in Review

Raymond James Financial increased its CRISPR Therapeutics (CRSP) stake by 5.3% in Q2 2026, buying an estimated $617K and bringing the position to 231,988 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

Raymond James Financial first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Raymond James Financial held 231,988 shares of CRISPR Therapeutics worth $12.7M as of Q2 2026.
  • Raymond James Financial bought 11,714 CRISPR Therapeutics shares in Q2 2026, an estimated $617K.
  • CRISPR Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1952 holding.
  • Raymond James Financial first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.